• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <1.0 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by the ability of the immobilized protein to inhibit the adhesion of HUVEC human umbilical vein endothelial cells. When 5 x 10    ⁴ cells/well are added to Recombinant Human Cadherin-13 (Catalog # 3264-CA) coated plates, cell adhesion is inhibited in a dose dependent manner after 2.5 hours at 37 °C. The ED    ₅₀ for this effect is 1.0‑5.0 μg/mL.

• Source

  Mouse myeloma cell line, NS0-derived Met1-Gly693, with a C-terminal 6-His tag

• Accession #

• N-terminal Sequence    
  Analysis

  Ala22

• Predicted Molecular Mass

  74.4 kDa

• SDS-PAGE

  100-120 kDa, reducing conditions

Background: Cadherin-13

Cadherin-13, also known as T-Cadherin and H‑Cadherin, is a GPI-anchored protein belonging to the Cadherin superfamily of calcium-dependent adhesion molecules. Cadherins are involved in multiple processes including embryonic development, cell migration, and maintenance of epithelial integrity (1, 2). Following removal of its C‑terminal propeptide, Cadherin-13 is expressed on the cell surface both with and without its N-terminal propeptide in species of approximately 120 kDa and 100 kDa, respectively (3, 4). Mouse Cadherin-13 contains five tandem Cadherin repeats and shares 95% and 98% aa sequence identity with human and rat Cadherin-13, respectively (5). It is most highly expressed in the circulatory and nervous systems, particularly on cardiac myocytes, vascular endothelial and smooth muscle cells, and neurons and astrocytes in the brain (3, 4, 6 - 9). Cadherin-13 exerts a negative influence on neurite extension, and it is down‑regulated in neurons upon NGF stimulation (10, 11). Homotypic Cadherin-13 interactions promote intercellular adhesion which can be inhibited by its binding to LDL (12). Cadherin-13 also mediates the cardioprotective effects of Adiponectin by directly binding Adiponectin (selectively the hexameric and HMW forms) and trapping it on vascular endothelial cells and cardiomyocytes (6 ‑ 8). The role of Cadherin-13 in the vasculature is complex. When expressed on vascular endothelial cells it promotes angiogenesis, but when expressed on stromal cells it inhibits neovascularization (13, 14). Its down‑regulation on breast carcinoma cells and up‑regulation on the vasculature of various tumors limits tumor cell proliferation and angiogenesis but also enhances tumor progression (4, 8, 15).

• References:

1. Pokutta, S. and W.I. Weis (2007) Annu. Rev. Cell Dev. Biol. 23:237.

2. Philippova, M. et al. (2009) Cell. Signal. 21:1035.

3. Stambolsky, D.V. et al. (1999) Biochim. Biophys. Acta 1416:155.

4. Doyle, D.D. et al. (1998) J. Biol. Chem. 273:6937.

5. Wyder, L. et al. (2000) Cancer Res. 60:4682.

6. Denzel, M.S. et al. (2010) J. Clin. Invest. 120:4342.

7. Hug, C. et al. (2004) Proc. Natl. Acad. Sci. 101:10308.

8. Hebbard, L.W. et al. (2008) Cancer Res. 68:1407.

9. Takeuchi, T. et al. (2000) J. Neurochem. 74:1489.

10. Fredette, B.J. et al. (1996) Development 122:3163.

11. Bai, S. et al. (2007) J. Biol. Chem. 282:27171.

12. Resink, T.J. et al. (1999) FEBS Lett. 463:29.

13. Philippova, M. et al. (2006) Arterioscler. Thromb. Vasc. Biol. 26:2222.

14. Rubina, K. et al. (2007) Angiogenesis 10:183.

15. Lee, S.W. (1996) Nat. Med. 2:776.

• Entrez Gene IDs:

  1012 (Human); 12554 (Mouse); 192248 (Rat)

• Alternate Names:

  cadherin 13, H-cadherin (heart); Cadherin13; Cadherin-13; CDH13; CDHHT-cadherin; H-Cadherin; Heart cadherin; heart-cadherin; P105; T-cad; T-Cadherin; Truncated cadherin; truncated-cadherin